



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : John Jeffrey Talley et al.  
Serial No. : 10/657,753  
Filed : September 8, 2003  
Title : INHIBITORS OF FUNGAL INVASION

Art Unit : 1645  
Examiner : Unknown

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449.

This statement is being filed within three months of the filing date of the application or before the receipt of a first Office action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No.: 14184-004001.

Respectfully submitted,

Date: 11 MAY 2004

  
Anita L. Meiklejohn, Ph.D.  
Reg. No. 35,283

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

20811590.doc


CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

May 11, 2004  
Date of Deposit

Bethany Slack  
Signature

BETHANY SLACK  
Typed or Printed Name of Person Signing Certificate

Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
14184-004001Application No.  
10/657,753**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant  
John Jeffrey Talley et al.Filing Date  
September 8, 2003Group Art Unit  
1645**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,378,715	01/03/1995	Stein et al.	514	329	
	AB	5,594,021	01/14/1997	Chan et al.	514	378	
	AC	5,833,946	11/10/1998	Tamburini et al.	424	9.2	
	AD	5,856,507	01/05/1999	Polniaszek et al.	548	241	
	AE	5,916,907	06/29/1999	Bird	514	374	
	AF	5,939,446	08/17/1999	Murugesan et al.	514	380	
	AG	6,043,265	03/28/2000	Murugesan et al.	514	374	
	AH	6,107,320	08/22/2000	Murugesan et al.	514	379	
	AI	6,248,767	06/19/2001	Blok et al.	514	380	
	AJ	6,271,248	08/07/2001	Murugesan et al.	514	375	
	AK	6,313,308	11/06/2001	Singh et al.	548	235	

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL	94/27979	12/08/1994	WIPO				
	AM	96/31492	10/10/1996	WIPO				
	AN	98/13366	04/02/1998	WIPO				
	AO	98/49162	11/05/1998	WIPO				


**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AP	Alex et al., "COS1, a two-component histidine kinase that is involved in hyphal development in the opportunistic pathogen <i>Candida albicans</i> ", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 95, pp. 7069-7073 (1998)
	AQ	Alonso-Monge et al., "Role of the Mitogen-Activated Protein Kinase Hog1p in Morphogenesis and Virulence of <i>Candida albicans</i> ", <u>J. Bacteriology</u> , Vol. 181, pp. 3058-3068 (1999)
	AR	Baillie et al., "Candida Biofilms and Their Susceptibility to Antifungal Agents", <u>Methods in Enzymology</u> , Vol. 310, pp. 644-656 (1999)
	AS	Bremm et al., "Influence of Azole Compounds on Adhesion, germ Tube Formation and Virulence of <i>C. Albicans</i> in Cell Cultures and Infected Animals", <u>Candida and Candidamycosis</u> , (E. Tumbay, Ed.), Plenum Press, New York, pp. 97-100 (1991)

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14184-004001	Application No. 10/657,753
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>John Jeffrey Talley et al.</b>	
		Filing Date September 8, 2003	Group Art Unit 1645

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AT	Brenciaglia et al., "The Influence of Antifungal drugs on Adherence of Candida albicans to Buccal Epithelial Cells", <u>Chemioterapia</u> , Vol. 5, pp. 200-203 (1986)
	AU	Calera et al., "Defective Hyphal Development and Avirulence Caused by a Deletion of the SSK1 Response Regulator Gene in Candida albicans", <u>Infection and Immunity</u> , Vol. 68, pp. 518-525 (2000)
	AV	Csank et al., "Roles of the Candida albicans Mitogen-Activated Protein Kinase Homolog, Cek1p, in Hyphal Development and Systemic Candidiasis", <u>Infection and Immunity</u> , Vol. 66, pp. 2713-2721 (1998)
	AW	Ha et al., "Effects of Azole Antifungal Drugs on the Transition from Yeast Cells to Hyphae in Susceptible and Resistant Isolates of the Pathogenic Yeast Candida Albicans", <u>Antimicrobial Agents and Chemotherapy</u> , Vol. 43, pp. 763-768 (1999)
	AX	Kretschmar et al., "Germ Tubes and Proteinase Activity Contribute to Virulence of Candida albicans in Murine Peritonitis", <u>Infection and Immunity</u> , Vol. 67, pp. 6637-6642 (1999)
	AY	Lo et al., "Nonfilamentous C. albicans Mutants Are Avirulent", <u>Cell</u> , Vol. 90, pp. 939-949 (1997)
	AZ	Martin, "The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review", <u>J. Antimicrob. Chemother.</u> , Vol. 44, pp. 429-437 (1999)
	AAA	Murugesan, Natesan et al., "Biphenylsulfonamide Endothelin Antagonists: Structure-Activity Relationships of a Series of Mono- and Disubstituted Analogues and Pharmacology of the Orally Active Endothelin Antagonist 2'-Amino-N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1,1'-biphenyl]-2-sulfonamide (BMS-187308)", <u>J. Med. Chem.</u> , Vol. 41, pp. 5198-5218 (1998)
	ABB	Murugesan, Natesan et al., "Biphenylsulfonamide Endothelin Receptor Antagonists. 2. Discovery of 4'-Oxazolyl Biphenylsulfonamides as a New Class of Potent, Highly Selective ET <sub>A</sub> Antagonists", <u>J. Med. Chem.</u> , Vol. 41, pp. 3111-3117 (2000)
	ACC	Murugesan, Natesan et al., "Discovery of N-Isioxazolyl Biphenylsulfonamides as Potent Dual Angiotensin II and Endothelin A Receptor Antagonists", <u>J. Med. Chem.</u> , Vol. 45, pp. 3829-3835 (2002)
	ADD	Philpott-Howard et al., "Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia", <u>J. Antimicrob. Chemother.</u> , Vol. 31, pp. 973-984 (1993)
	AEE	Stein, Philip D. et al., "Discovery and Structure - Activity Relationships of Sulfonamide ET <sub>A</sub> -Selective Antagonists", <u>J. Med. Chem.</u> , Vol. 38, pp. 1344-1354 (1995)
	AFF	Van't Wout et al., "Effect of amphotericin B, fluconazole and itraconazole and intracellular Candida albicans and germ tube development in macrophages", <u>Antimicrob. Chemother.</u> , Vol. 25, pp. 803-811 (1990)
	AGG	Weig et al., "Clinical aspects and pathogenesis of Candida infection", <u>Trends in Microbiology</u> , Vol. 6, pp. 468-470 (1998)
	AHH	Wu, Chengde et al., "Endothelin Antagonists: Substituted Mesitylcarboxamides with High Potency and Selectivity for ET <sub>A</sub> Receptors", <u>J. Med. Chem.</u> , Vol. 42, pp. 4485-4499 (1999)
	AII	Wu, Chengde et al., "Discovery of TBC11251, a Potent, Long Acting, Orally Active Endothelin Receptor-A Selective Antagonist", <u>J. Med. Chem.</u> , Vol. 40, pp. 1690-1697 (1997)
	AJJ	Wu, Chengde et al., "Structure-Activity Relationships of N <sup>2</sup> -Aryl-3-(isoxazolylsulfamoyl)-2-thiophenecarboxamides as Selective Endothelin Receptor-A Antagonists", <u>J. Med. Chem.</u> , Vol. 40, pp. 1682-1689 (1997)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14184-004001	Application No. 10/657,753
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant John Jeffrey Talley et al.	
		Filing Date September 8, 2003	Group Art Unit 1645

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AKK	Wu, Chengde et al., "Acyl Substitution at the Ortho Position of Anilides Enhances Oral Bioavailability of the Thiophene Sulfonamides: TBC3214, an ET <sub>A</sub> Selective Endothelin Antagonist", J. Med. Chem., Vol. 44, pp. 1211-1216 (2001)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	